Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK-Novartis Consumer JV

Division of GlaxoSmithKline PLC

Latest From GSK-Novartis Consumer JV

Taisho Wraps BMS Consumer Health Acquisition; iAnthus Nabs CBD For Life; Health & Wellness M&A In Brief

Bristol-Myers Squibb is free to focus on drug development for patients facing serious diseases, with the divestment of its UPSA consumer health business to Taisho now complete. Separately, Harvest One Cannabis and iAnthus Capital Holdings build their capabilities to meet soaring demand for CBD and other cannabis-derived health, wellness and beauty products.

Health Wellness

Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations

Seven new drug applications got the thumbs up this week from the EMA's drug evaluation committee, the CHMP.  Their EU approval should now be a formality. Two new Shionogi treatments are set for approval, as are two orphan products – one from Medac, the other from AOP Orphan Pharmaceuticals. Pfizer got the OK for one biosimilar but has withdrawn an application for another.

Europe Regulation

CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?

With its final meeting of the year under way, the EMA's medicines evaluation committee, the CHMP, will bring seasonal cheer for some companies if it decides their products merit EU approval. New treatments from Shionogi and Medac are up for an opinion. A planned appearance by Portola before the panel to answers questions relating to its marketing application for Ondexxya/AndexXa has been cancelled and the review period for the marketing authorization application for the product extended.
Europe BioPharmaceutical

Accenture Prescribes A New Data Management Future For Medtechs

The value of revenue streams derived from new business models is increasingly defined by how well companies manage the data within their ecosystems. Managing the data in the "last mile" subset provides an opportunity for medtech companies to generate income in that revenue stream, says Maximilian Schmid, head of the Global MedTech Practice at Accenture Life Sciences. 

Digital Health Leadership
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register